Shades of gray between large B-cell lymphomas and Hodgkin lymphomas: differential diagnosis and biological implications

Harris, Nancy L.

doi:10.1038/modpathol.2012.182

Cited by 64 publications

(69 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are "gray-zone" lymphomas showing features, including immunophenotype, characteristic of both classical Hodgkin lymphoma, and primary mediastinal large B-cell lymphoma. 55 In addition to the expression of CD30 on some PTCL, NOS and those T-cell lymphomas characteristically positive for the antigen, CD30 may be expressed on adult T-cell leukemia/lymphoma cells, the human T-cell leukemia virusassociated malignancy. Here, CD30 is distinctly present on the large cells and may first appear when the patient relapses with a more aggressive looking lesion.…”

Section: Mature T-and B-cell Lymphomas: a Cd30 Surveymentioning

confidence: 99%

CD30: receptor, marker, target

Gottesman¹

2016

PLMI

View full text Add to dashboard Cite

CD30 is a member of the tumor necrosis factor receptor family and is expressed on activated lymphocytes and a few other normal cells. Its signaling activates NF-κB transcription factor, resulting in pleiotropic regulation of gene function. CD30 is the characteristic marker of classical Hodgkin lymphoma, anaplastic large-cell lymphoma, and embryonal cell carcinoma, and it is expressed on a subset of aggressive T-and B-cell neoplasms. Its restricted expression on normal cells makes it an attractive candidate for targeted therapy. The underlying molecular alterations in these malignancies serve to explain the need for a toxin-bound therapeutic reagent.

show abstract

Section: Mature T-and B-cell Lymphomas: a Cd30 Surveymentioning

confidence: 99%

CD30: receptor, marker, target

Gottesman¹

2016

PLMI

View full text Add to dashboard Cite

show abstract

“…These molecular findings further support the previous clinical and pathological observation of a very close relationship between PMBL and particularly mediastinal classical HL (cHL) (reviewed in this issue by Harris). 61,62 Together with more recent genetic and epigenetic studies, they also support the inclusion in the WHO classification of the category large B-cell lymphoma, unclassifiable with features intermediate between DLBCL and HL. [63][64][65][66] …”

Section: Characterization Of Known Entities and Recognition Of New Camentioning

confidence: 65%

Whole genome profiling and other high throughput technologies in lymphoid neoplasms—current contributions and future hopes

Campo

2013

Modern Pathology

View full text Add to dashboard Cite

The development of high throughput technologies based on the knowledge of the human genome has opened the possibility to search for global genomic alterations in tumors responsible for their development and progression that may have important clinical implications. One of the major applications of this genomic knowledge has been the design of different types of microarray platforms for the analysis of DNA alterations and gene expression profiling (GEP). The main contributions of the DNA studies in lymphoid neoplasms include the definition of relatively characteristic genomic profiles for specific disease entities, the demonstration of common chromosomal alterations across entities, the identification of genes and pathways targeted by the altered chromosomal regions, and the identification of chromosomal alterations with prognostic implications. RNA GEP studies in these tumors have enhanced the molecular characterization of known entities and facilitated the recognition of new subtypes and categories of lymphoid neoplasms, the identification of new biomarkers and prognostic models, and the detection of oncogenic pathways with potential implications for targeted therapies. The recent development of the next generation sequencing (NGS) technologies and its application in lymphoid neoplasms already have provided an initial view of the complex landscape of somatic mutations in these tumors and some findings with important functional and clinical implications. This review addresses the major contributions and limitations of the microarray technologies in the understanding of lymphoid neoplasms and discusses how this knowledge may be transferred into the clinics. The initial results of the NGS studies are also presented.

show abstract

“…68 It is seen most frequently in young adults, with a slight female predominance and a rapidly growing mediastinal mass. The lymphoma cells are large, with round to slightly irregular nuclei, occasional pleomorphic multilobated nuclei, with moderate amounts of pale cytoplasm, imparting a clear cell appearance.…”

Section: Other Lymphomas Of Large B Cells Primary Mediastinal Large Bmentioning

confidence: 99%

Practical Applications in Immunohistochemistry: Evaluation of Diffuse Large B-Cell Lymphoma and Related Large B-Cell Lymphomas

O’Malley¹,

Auerbach²,

Weiss³

2015

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Context Diffuse large B-cell lymphoma is the most commonly diagnosed subtype of lymphoma worldwide. The current World Health Organization (WHO) classification includes several subtypes, based on a combination of clinical, immunohistochemical, and genetic differences. Immunohistochemical staining is essential in evaluating diffuse large B-cell lymphoma and many related large B-cell lymphomas and aggressive B-cell lymphomas. Objective To address different immunohistochemical features used for identification, subclassification, prognosis and in some cases, therapy, of diffuse large B-cell lymphoma and related lymphomas. Data Sources The information outlined in this review article is based on our experiences with routine cases, on the current WHO classification of hematopoietic and lymphoid tumors, and on a review of English-language articles published throughout 2014. Conclusions Features and diagnostic criteria of diffuse large B-cell lymphoma, aggressive variants of B-cell lymphomas, including Burkitt lymphoma and “double-hit” lymphomas, are discussed. Identification of cell of origin (germinal center type versus activated B-cell type) is discussed at length. Finally, practical approaches for diagnosis are discussed.

show abstract

Shades of gray between large B-cell lymphomas and Hodgkin lymphomas: differential diagnosis and biological implications

Cited by 64 publications

References 26 publications

CD30: receptor, marker, target

CD30: receptor, marker, target

Whole genome profiling and other high throughput technologies in lymphoid neoplasms—current contributions and future hopes

Practical Applications in Immunohistochemistry: Evaluation of Diffuse Large B-Cell Lymphoma and Related Large B-Cell Lymphomas

Contact Info

Product

Resources

About